Brief: Checkpoint Therapeutics Announces Positive Topline Results From The Registration-Enabling Trial Of Cosibelimab In Metastatic Cutaneous Squamous Cell Carcinoma
25/01/2022 13:54
Jan 25 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
THE REGISTRATION-ENABLING TRIAL OF COSIBELIMAB IN METASTATIC
CUTANEOUS SQUAMOUS CELL CARCINOMA
* CHECKPOINT THERAPEUTICS INC - SAFETY AND TOLERABILITY
PROFILE
CONSISTENT WITH PREVIOUSLY REPORTED DATA
* CHECKPOINT THERAPEUTICS INC - STUDY MET ITS PRIMARY
ENDPOINT,
WITH COSIBELIMAB DEMONSTRATING A CONFIRMED OBJECTIVE RESPONSE
RATE ("ORR") OF 47.4%
* CHECKPOINT THERAPEUTICS INC - PLANNED BLA SUBMISSION ON
TRACK
FOR LATER THIS YEAR
Source text for Eikon: ID:nGNX4LZgpq
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say